Free Trial

Ardelyx (ARDX) Competitors

Ardelyx logo
$4.48 +0.13 (+2.99%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$4.51 +0.03 (+0.67%)
As of 09:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARDX vs. MRUS, ACLX, ACAD, SWTX, RARE, AAPG, PTGX, RNA, SRRK, and MLTX

Should you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Merus (MRUS), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Protagonist Therapeutics (PTGX), Avidity Biosciences (RNA), Scholar Rock (SRRK), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.

Ardelyx vs. Its Competitors

Merus (NASDAQ:MRUS) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Ardelyx has higher revenue and earnings than Merus. Ardelyx is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merus$36.13M100.24-$215.33M-$4.08-12.83
Ardelyx$361.71M2.96-$39.14M-$0.22-20.36

Ardelyx has a net margin of -14.86% compared to Merus' net margin of -506.73%. Ardelyx's return on equity of -34.45% beat Merus' return on equity.

Company Net Margins Return on Equity Return on Assets
Merus-506.73% -35.99% -29.83%
Ardelyx -14.86%-34.45%-13.81%

Merus has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Ardelyx has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.

In the previous week, Ardelyx had 5 more articles in the media than Merus. MarketBeat recorded 9 mentions for Ardelyx and 4 mentions for Merus. Merus' average media sentiment score of 1.14 beat Ardelyx's score of 0.61 indicating that Merus is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Merus
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ardelyx
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Merus currently has a consensus target price of $84.64, suggesting a potential upside of 61.74%. Ardelyx has a consensus target price of $10.89, suggesting a potential upside of 143.06%. Given Ardelyx's higher probable upside, analysts plainly believe Ardelyx is more favorable than Merus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Merus
0 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
3.14
Ardelyx
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.00

96.1% of Merus shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 4.6% of Merus shares are held by insiders. Comparatively, 4.8% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Ardelyx beats Merus on 9 of the 17 factors compared between the two stocks.

Get Ardelyx News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARDX vs. The Competition

MetricArdelyxMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.07B$2.68B$5.50B$8.94B
Dividend YieldN/A1.79%5.25%4.04%
P/E Ratio-20.368.9826.9720.11
Price / Sales2.96714.59426.02119.76
Price / CashN/A159.8036.8257.86
Price / Book6.144.517.985.56
Net Income-$39.14M$31.26M$3.16B$248.40M
7 Day Performance6.92%3.57%2.36%4.67%
1 Month Performance19.15%1.28%2.15%6.64%
1 Year Performance-19.42%1.08%33.78%21.31%

Ardelyx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARDX
Ardelyx
4.4362 of 5 stars
$4.48
+3.0%
$10.89
+143.1%
-17.8%$1.07B$361.71M-20.3690
MRUS
Merus
2.0988 of 5 stars
$52.60
-0.7%
$84.64
+60.9%
-6.1%$3.64B$54.73M-12.8937News Coverage
Positive News
ACLX
Arcellx
2.3004 of 5 stars
$65.85
+0.8%
$111.23
+68.9%
+19.3%$3.63B$107.94M-22.0280
ACAD
ACADIA Pharmaceuticals
4.6769 of 5 stars
$21.57
-2.5%
$27.88
+29.2%
+28.8%$3.61B$996.28M15.74510
SWTX
SpringWorks Therapeutics
1.5425 of 5 stars
$46.99
+0.0%
$52.57
+11.9%
N/A$3.54B$191.59M-13.78230
RARE
Ultragenyx Pharmaceutical
4.0685 of 5 stars
$36.36
-0.4%
$87.00
+139.3%
-5.0%$3.44B$590.69M-6.181,294
AAPG
Ascentage Pharma Group International
N/A$39.38
-0.6%
N/AN/A$3.43B$134.35M0.00600News Coverage
Positive News
PTGX
Protagonist Therapeutics
2.3405 of 5 stars
$55.27
-0.8%
$66.10
+19.6%
+43.3%$3.43B$434.43M73.69120News Coverage
RNA
Avidity Biosciences
2.4663 of 5 stars
$28.40
-2.2%
$65.59
+130.9%
-24.3%$3.42B$10.90M-9.47190
SRRK
Scholar Rock
3.3139 of 5 stars
$35.42
-1.1%
$42.67
+20.5%
+335.1%$3.36B$33.19M-14.00140
MLTX
MoonLake Immunotherapeutics
2.1668 of 5 stars
$47.20
-0.7%
$74.50
+57.8%
+7.4%$3.02BN/A-20.522News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:ARDX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners